tb 500 bpc 157 blend benefits What Science ACTUALLY Says About bpc 157 and tb 500

According to CMS billing guidance (Medicare Article A57755), the primary covered indications are pernicious anemia, documented cobalamin deficiency with laboratory evidence, and malabsorption syndromes that prevent adequate oral B12 absorption

The FDA placed it in 503A Category 2 ("may present significant safety risks") in 2023, effectively barring compounding pharmacies from using it, then removed it from that category in April 2026 after nominators withdrew their submission, without adding it to the approved Category 1 compounding list

The product leaves the warehouse at 2 to 8 C and should arrive within the same window

For systemic or musculoskeletal targets, injectable has a pharmacokinetic advantage